View the full Defeat GBM Research Collaborative website at www.DefeatGBM.org.
Glioblastoma multiforme (GBM) research is on the cusp of genetic and molecular discoveries that will forever alter current diagnostic, prognostic, and therapeutic achievements. A highly aggressive and complex brain tumor type, GBM tumors are also one of the most devastating forms of cancer, effecting thousands of Americans each day. As such, we believe it is our duty to drive the advancement of this research area to understand how to combat its resistance and adaptability, and deliver new and effective therapies to improve patient survival.
With this in mind, the National Brain Tumor Society created the Defeat GBM Research Collaborative, its largest and boldest research initiative to date which aims to significantly improve the survival rate of patients who are battling glioblastoma multiforme (GBM). Through robust collaborations comprised of the world’s leaders committed to advances in cancer research, multiple and synergistic projects are driven by investigator teams with proven track records of results to create significant progress in scientific discovery, therapeutic (drug) development, and the availability of new treatments – more quickly. This collaborative model also allows for better knowledge transfer and data sharing among all the projects contained within the Defeat GBM Research Collaborative to ensure each project is aligned toward a unified goal.
A team of senior brain cancer experts acting as the Strategic Scientific Advisory Council (SSAC) will partner with the National Brain Tumor Society to ensure overall goal attainment and success. In addition, the Advisors will play a role in evaluating additional GBM research projects taking place throughout the United States, as well as around the world. Additional projects will be evaluated on their scientific potential, as well as their ability to support the patient-centric and outcome-driven goals of the Defeat GBM Research Collaborative. With this lens, the Advisors will help to ensure that only the most promising science is funded.
Additional and unique aspects of this program are the simultaneous efforts in basic scientific research, translational science, pre-clinical drug development, and improved clinical trial design - all intended to quicken the pace of discovery, transfer target knowledge to drug development, and identify patient biomarker panels to improve clinical trials.
To learn more or make a contribution toward the Defeat GBM Research Collaborative, please contact Kevin Courtney, Chief Development Officer, at email@example.com.